StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Vikas Salunkhe, Nirmal Bang Securities

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byVikas Salunkhe, Nirmal Bang SecuritiesHorizon: NA (inferred Swing (≤2wk))9 Jun 2026via CNBC Awaaz.

Entry₹2,209.6Inferred
Target₹2,290
Total upside +3.64% (call closed)
Stop lossNot given
At expiry₹2,19222 Jun 2026, 3:30 pm
Expired-0.80%
Follow Vikas Salunkhe for new calls(27% target hit, 130 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 1 active Swing call on GLENMARKSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 11:52 pm IST
3 supporting3 neutral0 opposing
Supports the BUY call (3)

Glenmark Pharmaceuticals Inc., USA launched Methylene Blue Injection USP, potentially increasing revenue.

BSE · Company Update·17 Jun · 5d ago

(opens in new tab)

Glenmark Pharmaceuticals Inc., USA has launched Lacosamide Injection USP, 200 mg/ 20mL (10 mg/mL), Single-Dose Vials.

BSE · Company Update·5 Jun · 2w ago

(opens in new tab)

Glenmark Pharma FY26 PAT Rises 30.1% to ₹13,620 Million; Q4 EBITDA Jumps to ₹9.4b

NewsGoogle News·1 Jun · 3w ago

(opens in new tab)
Neutral / worth noting (3)

Glenmark transfers nebulizer brands to subsidiary for ₹223 Cr

NewsGoogle News·30 May · 3w ago

(opens in new tab)

Press Release and Management Discussion & Analysis for the Fourth Quarter ended March 31, 2026.

BSE · Company Update·29 May · 3w ago

(opens in new tab)

The Board of Directors of Glenmark Pharmaceuticals Limited considered and approved audited financial results and recommended dividend.

BSE · Board Meeting·29 May · 3w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Vikas Salunkhe, Nirmal Bang Securities

Every call and its outcome